Natasha de Alwis, Natalie K Binder, Sally Beard, Yeukai Tm Mangwiro, Elif Kadife, James Sm Cuffe, Emerson Keenan, Bianca R Fato, Tu'uhevaha J Kaitu'u-Lino, Fiona C Brownfoot, Sarah A Marshall, Natalie J Hannan
Preeclampsia affects ∼2-8% of pregnancies worldwide. It is associated with increased long-term maternal cardiovascular disease risk. This study assesses the effect of the vasoconstrictor N(ω)-nitro-L-arginine methyl ester (L-NAME) in modelling preeclampsia in mice, and its long-term effects on maternal cardiovascular health. In this study, we found that L-NAME administration mimicked key characteristics of preeclampsia, including elevated blood pressure, impaired fetal and placental growth, and increased circulating endothelin-1 (vasoconstrictor), soluble fms-like tyrosine kinase-1 (anti-angiogenic factor), and C-reactive protein (inflammatory marker)...
August 5, 2022: Life Science Alliance